Clinical Trial Design Based on Time to Death/Progression.

about

Update in Interstitial Lung Disease 2016.

P2860

Q49734357-CFE89F9D-017F-4339-87C3-921729044944

P2860

Clinical Trial Design Based on Time to Death/Progression.

Item

http://www.wikidata.org/entity/Q51810369

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Clinical Trial Design Based on Time to Death/Progression.

@en

Clinical Trial Design Based on Time to Death/Progression.

@nl

type

Item

label

Clinical Trial Design Based on Time to Death/Progression.

@en

Clinical Trial Design Based on Time to Death/Progression.

@nl

prefLabel

Clinical Trial Design Based on Time to Death/Progression.

@en

Clinical Trial Design Based on Time to Death/Progression.

@nl

P1476

Clinical Trial Design Based on Time to Death/Progression.

@en

P2093

Kevin R Flaherty

http://www.w3.org/2001/XMLSchema#string

P2860

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Predicting pulmonary fibrosis disease course from past trends in pulmonary function.

Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events.

Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

Surrogate endpoints in clinical trials: definition and operational criteria.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

P304

653-654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201604-0819ED

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

194

http://www.w3.org/2001/XMLSchema#string

P50

Susan Murray

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27628074

http://www.w3.org/2001/XMLSchema#string

Clinical Trial Design Based on Time to Death/Progression.

about

P2860

P2860

Clinical Trial Design Based on Time to Death/Progression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698